IFNA1 and psoriasis: These findings support previous reports implicating type I and type II IFN dysregulation in psoriasis (73, 74) and PsA (75) that may be the target of therapeutic interventions, e.g. with Janus kinase (JAK) inhibitors that are now approved for the treatment for moderate to severe psoriasis and PsA patients who have had an inadequate response or intolerance to methotrexate or other DMARDs (76–78) (79).